2,3-difluoro-5-methylbenzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,3-difluoro-5-methylbenzamide
• 英文别名: 2,3-Difluoro-5-methylbenzamide
• 化学式: C₈H₇F₂NO
• 分子量: 171.146
• InChiKey: CKGSPXRNVWMJNX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2,3-difluoro-5-methylbenzamide 在 三氯氧磷 作用下， 以 乙腈 为溶剂， 生成 2,3-二氟-5-甲基苯腈
  参考文献：
  名称：

  [EN] GPR52 MODULATORS AND METHODS OF USE
  [FR] MODULATEURS DE GPR52 ET PROCÉDÉS D'UTILISATION

  摘要：

  The present disclosure relates to compounds of Formula (I) that modulate the activity of G-protein coupled receptor 52 (GPR52), pharmaceutically acceptable salts of compounds of Formula (I), and pharmaceutical compositions thereof. Compounds, pharmaceutical salts of compounds, and pharmaceutical compositions of the present disclosure are directed to methods useful in the treatment or prophylaxis of a neurological disease or disorder and conditions related thereto.

  公开号：

  WO2022232017A1
• 作为产物：
  描述：

  2,3-二氟-5-甲基苯甲酸 在 氯化亚砜 、 ammonium hydroxide 作用下， 以 二氯甲烷 为溶剂， 以14.73 g的产率得到2,3-difluoro-5-methylbenzamide
  参考文献：
  名称：

  [EN] GPR52 MODULATORS AND METHODS OF USE
  [FR] MODULATEURS DE GPR52 ET PROCÉDÉS D'UTILISATION

  摘要：

  The present disclosure relates to compounds of Formula (I) that modulate the activity of G-protein coupled receptor 52 (GPR52), pharmaceutically acceptable salts of compounds of Formula (I), and pharmaceutical compositions thereof. Compounds, pharmaceutical salts of compounds, and pharmaceutical compositions of the present disclosure are directed to methods useful in the treatment or prophylaxis of a neurological disease or disorder and conditions related thereto.

  公开号：

  WO2022232017A1

文献信息

• THERAPEUTIC COMPOUNDS
  申请人：Gilead Sciences, Inc.

  公开号：US20140303164A1

  公开（公告）日：2014-10-09

  Compounds of formula I: or salts thereof are disclosed. Also disclosed are pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.

  公开了化学式I的化合物或其盐。还公开了包含化学式I化合物的药物组合物，制备化学式I化合物的方法，用于制备化学式I化合物的中间体以及治疗反转录病毒感染的治疗方法，包括由HIV病毒引起的感染。
• AMIDE COMPOUNDS FOR THE TREATMENT OF HIV
  申请人：Gilead Sciences, Inc.

  公开号：EP2961742B1

  公开（公告）日：2018-08-01
• AMIDE COMPOUNDS FOR THE TREATMENT OF HIV INFECTIONS
  申请人：Gilead Sciences, Inc.

  公开号：EP3409667B1

  公开（公告）日：2021-07-21
• [EN] THERAPEUTIC COMPOUNDS<br/>[FR] COMPOSÉS THÉRAPEUTIQUES
  申请人：GILEAD SCIENCES INC

  公开号：WO2014134566A2

  公开（公告）日：2014-09-04

  Compounds of formula (I) or salts thereof are disclosed. Also disclosed are pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.
• [EN] GPR52 MODULATORS AND METHODS OF USE<br/>[FR] MODULATEURS DE GPR52 ET PROCÉDÉS D'UTILISATION
  申请人：[en]NEUROCRINE BIOSCIENCES, INC.

  公开号：WO2022232017A1

  公开（公告）日：2022-11-03

  The present disclosure relates to compounds of Formula (I) that modulate the activity of G-protein coupled receptor 52 (GPR52), pharmaceutically acceptable salts of compounds of Formula (I), and pharmaceutical compositions thereof. Compounds, pharmaceutical salts of compounds, and pharmaceutical compositions of the present disclosure are directed to methods useful in the treatment or prophylaxis of a neurological disease or disorder and conditions related thereto.